Antibody-Drug Conjugates Market Size, Share, Revenue Analysis 2032

Antibody-Drug Conjugates Market: Industry Perspective

The global antibody-drug conjugates market size was worth around USD 9.51 Billion in 2023 and is predicted to grow to around USD 23.55 Billion by 2032 with a compound annual growth rate (CAGR) of roughly 10.6% between 2024 and 2032. The report analyzes the global antibody-drug conjugates market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the antibody-drug conjugates industry.

Request Free Sample

The report covers forecast and analysis for the Antibody-Drug Conjugates market on a global and regional level. The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD Billion). The study includes drivers and restraints for the Antibody-Drug Conjugates market along with the impact they have on the demand over the forecast period.

Request Free Sample

Additionally, the report includes the study of opportunities available in the Antibody-Drug Conjugates market on a global level. In order to give the users of this report a comprehensive view of the Antibody-Drug Conjugates market we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein application, Technology, and regional segments are benchmarked based on their market size, growth rate and general attractiveness.

Antibody-Drug Conjugates Market: Overview

Antibody-drug conjugate is one of the biopharmaceutical drug classes that have been developed as a directed cancer therapy. Antibody-drug conjugates are intended, unlike chemotherapy, to target as well as destroy tumor cells while sparing healthy cells. By 2023, Antibody-drug conjugates had been developed by over 56 pharmaceutical companies. Antibody-drug conjugates are compound molecules made up of an antibody that is associated with a biologically active cytotoxic (anticancer) product.

Examples of bioconjugates and immunoconjugates are antibody-drug conjugates. Antibody-drug conjugates combine monoclonal antibodies targeting capabilities with cytotoxic drug cancer-killing capabilities. They can be designed to discriminate between tissue that is healthy and diseased.

Antibody-Drug Conjugates Market: Segmentation Analysis

The study provides a decisive view of the Antibody-Drug Conjugates market by segmenting the market based on application, technology and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.

Based on application, the market is segmented into blood cancer, breast cancer, ovarian cancer, lung cancer, and brain tumor. Breast cancer was the largest segment generating revenue in 2023 due to factors such as high global breast cancer incidence and Kadcyla commercial availability in most major regions. One of the major drivers of the antibody-drug conjugate market is the increasing prevalence of cancer. According to the World Health Organization (WHO), the most common applications of cancer in 2018 are breast cancer with 2,09 million cases, 2,09 million cases of lung cancer, 1,80 million cases of colorectal cancer, 1,28 million cases of prostate cancer, 1,04 million cases of skin cancer, and 1,03 million cases of stomach cancer.

Based on the Technology segment, the market is bifurcated into cleavable and non-cleavable linkers. Because of factors such as the large use of these linkers and the total number of products in the pipeline, it has been projected that cleavable linkers would see the fastest growth over the forecast period. In addition, two new products from Pfizer–Besponsa and Mylotarg–were approved for use in developed regions in 2017 and both feature cleavable connectors.

Antibody-Drug Conjugates Market: Report Scope

Antibody-Drug Conjugates Market: Regional Analysis

The geographical segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America was the largest manufacturing country in 2023, followed by Europe. The main factor attributing to their continued dominance is the presence of major market players such as Seattle Genetics, Roche, Pfizer, and AbbVie.

North America is the most well-established market for using ADCs combined with well-established healthcare infrastructure and knowledge of patients. As most of the ADCs currently in the pipeline are being produced in the U.S., North America is expected to see the fastest growth over the forecast period. Sometimes, the United States. One of the first governing bodies to allow ADC in the United States is the Food and Drug Administration (FDA). Therefore, over the forecast period, these factors are likely to fuel market growth in the region.

The increasing acceptance and therapeutic potential of ADCs can also be associated with an exponential increase in the number of patents submitted/granted; the total number of patents rose from 1,395 in 2009 to around 16,500 in the first half of 2019. rose from 1,395 in 2009 to around 16,500 in the first half of 2019.  With more than 200 ADCs being developed in clinical/preclinical stages, the industry is gradually shifting from relying on conventional technologies to new and more robust approaches to conjugate such complex biomolecules.

With more than 200 ADCs being developed in clinical/preclinical stages, the industry is gradually shifting from relying on conventional technologies to new and more robust approaches to conjugate such complex biomolecules. A variety of well-funded start-ups / small businesses have been developed over the years, offering new conjugation techniques, more powerful warheads and advanced connecting technologies. In addition, over the past few years, several licensing agreements/collaborations between drug developers and software providers have been inked to advance the creation of candidates for pipeline ADC.

Antibody-Drug Conjugates Market: Competitive Analysis

Some of the major players in the global antibody-drug conjugates market include:

• AbbVie Inc.
• Agensys Inc.
• Celldex Therapeutics Inc.
• Concortis Biotherapeutics
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Sanofi S.A.
• Seattle Genetics Inc.
• Synthon Holding B.V.
• Takeda Pharmaceutical Company Limited

The report segments the global Antibody-Drug Conjugates market as follows:

By Application Segment Analysis

• Blood Cancer
  • Leukemia
  • Lymphoma
• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Brain Tumor

By Technology Segment Analysis

• Cleavable Linker
• Non-cleavable Linker

By Regional Segment Analysis

• North America
  • U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa